Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Retained Earnings: 2011-2024

Historic Retained Earnings for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to -$308.6 million.

  • Adma Biologics' Retained Earnings rose 49.81% to -$211.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.0 million, marking a year-over-year increase of 49.81%. This contributed to the annual value of -$308.6 million for FY2024, which is 39.05% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Retained Earnings is -$308.6 million, which was up 39.05% from -$506.3 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Retained Earnings ranged from a high of -$308.6 million in FY2024 and a low of -$506.3 million during FY2023.
  • For the 3-year period, Adma Biologics' Retained Earnings averaged around -$431.0 million, with its median value being -$478.0 million (2022).
  • In the last 5 years, Adma Biologics' Retained Earnings declined by 21.04% in 2021 and then soared by 39.05% in 2024.
  • Adma Biologics' Retained Earnings (Yearly) stood at -$340.5 million in 2020, then decreased by 21.04% to -$412.1 million in 2021, then dropped by 15.99% to -$478.0 million in 2022, then declined by 5.91% to -$506.3 million in 2023, then surged by 39.05% to -$308.6 million in 2024.